Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 20, Issue 5, 2002, Pages 1335-1343

  Socinski, Mark A ^a   Schell, Michael J ^a   Peterman, Amy ^a   Bakri, Kamal ^a   Yates, Steven ^a   Gitten, Robert ^a   Unger, Paul ^a   Lee, Joanna ^a   Lee, Ji Hyun ^a   Tynan, Maureen ^a   Moore, Martha ^a   Kies, Merrill S ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; QUALITY OF LIFE;

EID: 0036499649     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.5.1335     Document Type: Article

References (27)

1. Cancer Statistics, 2001
2. Non-small cell lung cancer: Part I. Biology diagnosis, and staging
3. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
4. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
5. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer
6. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung and stable disease after two or three cycles of MACC
7. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer
8. Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin
9. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
10. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
11. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small-cell lung cancer (NSCLC)
12. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small-cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial
13. A randomized phase III trial of four chemotherapy regimens in advanced non-small-cell lung cancer (NSCLC)
14. Patterns of practice survey for non-small cell lung cancer in the U.S
15. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
16. Reinduction of response with Taxol (T) in advanced breast cancer (ABC)
17. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
18. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument
19. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
20. Comparison of several model-based methods of analyzing incomplete QOL: Data in cancer clinical trials
21. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer: The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
22. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
23. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-smallcell lung cancer: A randomized phase III study of the Italian Lung Cancer Project
24. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
25. Evaluation of the optimal duration of chemotherapy in phase II trials for inoperable non-small cell lung cancer (NSCLC)
26. Patient preference for extended palliative chemotherapy for non-small cell lung cancer
27. Maintenance chemotherapy in advanced non-small-cell lung cancer (NSCLC): A randomized study of vinorelbine (V) versus observation (OB) in patients (Pts) responding to induction therapy (French Cooperative Oncology Group)